This HTML5 document contains 21 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

PrefixNamespace IRI
dcthttp://purl.org/dc/terms/
n4http://ns.inria.fr/covid19/1dae808f9f267204fec9c67d4b72a2b53a548c47#
covidprhttp://ns.inria.fr/covid19/property/
fabiohttp://purl.org/spar/fabio/
foafhttp://xmlns.com/foaf/0.1/
dcehttp://purl.org/dc/elements/1.1/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
n11https://doi.org/10.1101/2020.04.24.
bibohttp://purl.org/ontology/bibo/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
covidhttp://ns.inria.fr/covid19/
xsdhhttp://www.w3.org/2001/XMLSchema#
Subject Item
covid:1dae808f9f267204fec9c67d4b72a2b53a548c47
rdf:type
bibo:AcademicArticle fabio:ResearchPaper schema:ScholarlyArticle
rdfs:isDefinedBy
covid:dataset-1-2
dct:title
The anti-HIV Drug Nelfinavir Mesylate (Viracept) is a Potent Inhibitor of Cell Fusion Caused by the SARS-CoV-2 Spike (S) Glycoprotein Warranting further Evaluation as an Antiviral against COVID-19 infections
dce:creator
Jois3, Seetharama Musarrat1, Farhana Nabi1, Rafiq Kousoulas, Konstantin Chouljenko1, Vladimir Dahal3, Achyut
dct:source
BioRxiv
dct:abstract
n4:abstract
dct:issued
2020-04-24
bibo:doi
10.1101/2020.04.24.060376
dct:license
biorxiv
foaf:sha1
1dae808f9f267204fec9c67d4b72a2b53a548c47
schema:url
n11:060376
covidpr:hasTitle
n4:title
schema:publication
bioRxiv
covidpr:hasBody
n4:body_text